Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

Journal of Diabetes and its Complications

Volumn 12, Issue 4, 1998, Pages 181-186

  Fonseca, Vivian A ^a   Reynolds, Tammy ^a   Hemphill, Donna ^a   Randolph, Carol ^a   Wall, Jan ^a   Valiquet, Thomas R ^b   Graveline, Jane ^c   Fink, Louis M ^a  

^a Div of Endocrinology and Metabolism   (United States)

^b PFIZER INC   (United States)

^c Sankyo Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; INSULIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN; TROGLITAZONE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; BLOOD COAGULATION DISORDERS; CHROMANS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYSIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031802033     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(97)00109-8     Document Type: Article

References (27)

1. McGill J.B., Schneider D.J., Arfken C.L., Lucore C.L., Sobel B.E. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 43:1994;104-109.
2. Ganda O.P., Arkin C.F. Hyperfibrinogenemia. an important risk factor for vascular complications in diabetes Diabetes Care. 15:1992;1245-1250.
3. Galajda P., Martinka E., Mokan M., Kubisz P. Endothelial markers in diabetes mellitus. Thromb Res. 85:1997;63-65.
4. Ceriello A., Giacomello R., Colatutto A., Toboga C., Gonano F. Increased prothrombin fragment 1+2 in type I diabetic patients. Haemostasis. 22:1992;50-51.
5. Juhan-Vague I., Alessi M.C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 70:1993;138-143.
6. Jain S.K., Nagi D.K., Slavin B.M., Lumb P.J., Yudkin J.S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Med. 10:1993;27-32.
7. Hamsten A., Defaire U., Walldius G., Dahlon G., Szamosi A., Landov C., Blomback M., Wiman B. Plasminogen activator inhibitor in plasma. Risk factor for recurrent myocardial infarction Lancet. 2:1987;3-9.
8. Gray G.R.P., Yudkin J.S., Patterson D.L. Plasminogen activator inhibitor. A risk factor for myocardial infarction in diabetic patients Br Heart J. 69:1993;228-232.
9. Gray G.R.P., Yudkin J.S., Patterson D.L. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction. A role for plasminogen activator inhibitor? Br Heart J. 70:1993;530-536.
10. Ceriello A. Coagulation activation in diabetes mellitus. The role of hyperglycaemia and therapeutic prospects Diabetologia. 36:1993;1119-1125.
11. Rabie M.J., Blashill A., Furie B.C. Prothrombin fragment 1.2.3, a major product of prothrombin activation in human plasma. J Biol Chem. 261:1986;13210-13215.
12. Ceriello A., Giacomello R., Stel G., Morz E., Taboga C., Tonutti L., Pirisi M., Falleti E., Bartoli E. Hyperglycemia-induced thrombin formation in diabetes; the possible role of oxidative stress. Diabetes. 44:1995;924-928.
13. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1994;1188-1193.
14. Saltiel A.R., Olefsky J.M. Perspectives in diabetes. Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes. 45:1996;1661-1669.
15. National Diabetes Data Group Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1979;1039-1057.
16. DeClerk P.J., Alessim C., Verstreken M., Kruithof E.K.O., Juhan-Vague I., Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 71:1988;220-225.
17. Hursting M., Butman B., Steiner J., Moore B.M., Plank M.C., Szewczyk K.M., Bell M.L., Dombrose F.A. Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem. 39:1993;583-591.
18. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
19. Potter van Loon B.J., Kluft C., Radder J.K., Blankenstein M.A., Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism. 42:1993;954-959.
20. Grant P.J., Kruithof E.K.O., FeMey C.P., Felber J.P., Bachmann F. Short-term infusions of insulin, traicylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor 1 concentrations in man. Clin Sci. 79:1990;513-516.
21. Pandolfi A., Iacoviello L., Capani F., Vitacolonna E., Donati M.B., Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 39:1996;1425-1431.
22. Nagi D.K., Hendra T.J., Ryle A.J., Cooper T.M., Temple R.C., Clark P.M.S., Schneider A.E., Hales C.N., Yudkin J.S. The relationships of concentration of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non insulin-dependent) diabetic subjects. Diabetologia. 33:1990;532-537.
23. Nordt T.K., Schneider D.J., Sobel B.E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation. 89:1994;321-330.
24. Vague P., Juhan-Vague C., Alessi M.C., Badler C., Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 57:1987;326-328.
25. Nagi D.K., Yudkin J.S. Effects of Metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study in two ethnic groups. Diabetes Care. 16:1993;621-629.
26. Mehrabjian M., Peter J.B., Barnard R.J., Lusis A.J. Dietary regulation of fibrinolytic factors. Atherosclerosis. 84:1990;25-32.
27. Knobl P., Schernthaner G., Schnack C., Pietschmann P., Proidl S., Prager R., Vukovich T. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost. 71:1994;692-697.